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Abstract
BACKGROUND—Obesity is associated with poorly differentiated and advanced prostate cancer 
and increased mortality. In preclinical models, caloric restriction delays prostate cancer 
progression and prolongs survival. We sought to determine if weight loss (WL) in men with 
prostate cancer prior to radical prostatectomy affects tumor apoptosis and proliferation, and if WL 
effects other metabolic biomarkers.
METHODS—In this Phase II prospective trial, overweight and obese men scheduled for radical 
prostatectomy were randomized to a 5–8 week WL program consisting of standard structured 
energy-restricted meal plans (1200–1500 Kcal/day) and physical activity or to a control group. 
The primary endpoint was apoptotic index in the radical prostatectomy malignant epithelium. 
Secondary endpoints were proliferation (Ki67) in the radical prostatectomy tissue, body weight, 
body mass index (BMI), waist to hip ratio, body composition, and serum PSA, insulin, 
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triglyceride, cholesterol, testosterone, estradiol, leptin, adiponectin, interleukin 6, interleukin 8, 
insulin-like growth factor 1, and IGF binding protein 1.
RESULTS—Twenty-three patients were randomized to the WL intervention and twenty-one 
patients to the control group. Subjects in the intervention group had significantly more weight loss 
(WL:−3.7 ± 0.5 kg; Control:−1.6 ± 0.5 kg; p=0.007) than the control group and total fat mass was 
significantly reduced (WL:−2.1 ± 0.4; Control: 0.1 ± 0.3; p=0.015). There was no significant 
difference in apoptotic or proliferation index between the groups. Among the other biomarkers, 
triglyceride and insulin levels were significantly decreased in the WL compared to the control 
group.
CONCLUSIONS—In summary, this short-term WL program prior to radical prostatectomy 
resulted in significantly more WL in the intervention vs. the control group and was accompanied 
by significant reductions in body fat mass, circulating triglycerides, and insulin. However, no 
significant changes were observed in malignant epithelium apoptosis or proliferation. Future 
studies should consider a longer term or more intensive weight loss intervention.
Keywords
Prostate cancer; clinical trial; apoptosis; weight loss; inflammation; Ki67
INTRODUCTION
Obesity is associated with poorly differentiated and advanced prostate cancer, increased risk 
of biochemical failure following radical prostatectomy and radiation therapy, and increased 
prostate cancer mortality (1–8). Multifactorial mechanisms may explain the link between 
obesity and the increased risk of advanced prostate cancer. Insulin metabolism, IGF-1, IGF 
binding protein, altered serum levels of sex hormones, pro-inflammatory cytokines, and 
adipokines may be involved (9–12). Visceral obesity may play an important role in the link 
between obesity and development of prostate cancer. One study among men in China 
showed that men in the highest quartile of waist-to-hip ratio had an almost 3-fold increased 
risk of developing prostate cancer (13). Another study described that central body fat mass 
was associated with increased high-grade prostate cancer (14). Likewise, increased 
periprostatic fat mass was associated with higher Gleason grade (15–17).
Whether weight loss (WL) has the potential to delay prostate cancer progression is of great 
interest. In preclinical studies, energy restriction is well-known to decrease prostate cancer 
progression and prolong survival in mouse models (18–21). The IGF-AKT pathway, 
cytokines and adipokines, and microvessel density/vascular endothelial growth factor 
(VEGF) gene expression play a role in the decrease of prostate cancer progression in mouse 
models (18, 19, 21). However, evidence from human studies is inconclusive (22). To 
examine if WL has the potential to slow the progression of prostate cancer, we designed a 
prospective randomized pre-prostatectomy trial to determine whether WL from a 
hypocaloric diet and increased physical activity results in anti-proliferative and pro-apoptotic 
effects on prostate cancer tissue histopathology. Other examined endpoints included weight 
change, body composition and fat depots, and concentrations of potential mechanistic 
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markers such as serum lipids, cholesterol, insulin, IGF-1, IGFBP-3, leptin, adiponectin, 
IL-6, IL-8, testosterone, and estradiol.
MATERIALS AND METHODS
Patient Eligibility and Recruitment
Participants were recruited from the urology clinics at the Veterans Administration Greater 
Los Angeles Healthcare System, UCLA, and Santa Monica UCLA from 2009 to 2013. 
Inclusion criteria included BMI of > 25 kg/m2, physical ability to undergo a physical activity 
intervention, and able to come to the VA Clinical Research Center for 7 study visits if 
randomized to the WL group. Subjects were ineligible if they had Gleason score >4+5=9, a 
history of receiving androgen deprivation therapy, antiandrogen therapy, finasteride, 
radiotherapy, or cryotherapy. Patients were also excluded if they had a history of diabetes 
and were receiving insulin, if they were taking weight loss medication or enrolled in a 
weight loss program, taking lycopene supplements, or had significant co-morbidities (i.e. 
cardiac, pulmonary, liver disease, and ongoing alcohol/drug abuse) or a cardiac pacemaker. 
The study was approved by the Institutional Review Boards at the VA and UCLA and 
registered with ClinicalTrial.gov (NCT#00475982).
Study Design
This was a randomized two-arm open label intervention study. All subjects signed informed 
consent documents prior to study entry. Subjects were randomized using a permuted block 
design to either a weight loss program or control group.us After randomization, baseline 
weight, height, waist, hip circumference, and body composition by dual-energy X-ray 
absorptiometry (DEXA) (GE Lunar DEXA, Chicago, IL; maximum weight capacity 350 
lbs) were determined, and fasting blood was collected. The control group proceeded with the 
scheduled radical prostatectomy. Within 3 days prior to radical prostatectomy, the control 
group had one additional visit to the clinical research center (CRC) for measurement of 
weight, height, waist, hip circumference, and fasting blood collection. Performance of a 
second DEXA scan in the control group prior to radical prostatectomy was added as a 
protocol modification after the beginning the trial, and therefore the first nine participants in 
the control group did not have an end of study DEXA scan. The control group was offered a 
free weight loss program after prostatectomy.
Subjects randomized to the WL group received one of two standard structured energy-
restricted meal plans (1200 and 1500 Kcal/day) using commercially available meal 
replacements and portion-controlled foods. Patients were taught how to count portions and 
how to consume the recommended calories from commercial ready-made frozen dinners. 
Prescribed plans were based upon lean body mass as determined by DEXA. The goal of the 
meal plan was to provide a total calorie intake incorporating 500–800 calorie deficits per 
day. Subjects had weekly visits with the CRC dietitian for the first 4 weeks, and every 2-
week visits for the following 4 weeks and received instruction on recipes, grocery shopping 
strategies, education on healthy food preparation, and preparation of meal replacements. 
Prior to each visit, subjects in the WL group completed a 3-day food record to promote 
compliance and as a tool to assist the dietician with counseling. Subject’s wives or life 
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partners were encouraged to attend and participate in the sessions. The goal for 
recommended diets was to contain 20–25% energy from fat, 15–20% from protein, and 50–
65% from carbohydrates largely from fruits and vegetables with some whole grains. Fiber 
recommendations were a total of 25 grams/day from fruits, vegetables, legumes, and high 
fiber cereals.
Patients in the WL group were counseled on performing 1 hour of exercise/day including 
aerobic, resistance, and flexibility activities such as walking and stretching. As an exercise 
incentive, patients were provided pedometers (Omron HJ-112 Digital Premium Pedometer, 
Bannockburn, IL) and exercise logs to complete and results were reviewed with the dietitian 
at each visit. As shown by Bravata et al., the use of pedometers is associated with significant 
increase in physical activity (23). Following the 5 to 8-week weight loss intervention and 
within 3 days prior to radical prostatectomy, weight, height, and waist to hip ratio were 
measured, fasting serum for biomarker analysis collected, and a DEXA scan was performed.
Outcomes
The primary endpoint was apoptotic index in the radical prostatectomy malignant 
epithelium. Secondary endpoints were proliferation (Ki67) in the radical prostatectomy 
malignant epithelium, body weight, BMI, waist to hip ratio, body composition, and serum 
PSA, insulin, triglyceride, cholesterol, testosterone, estradiol, leptin, adiponectin, IL-6, IL-8, 
IGF-1, and IGFBP-1 levels.
Serum Analyses
Serum PSA, triglyceride, total cholesterol, LDL- and HDL-cholesterol, insulin, testosterone, 
and estradiol were measured by the UCLA clinical laboratory using standard laboratory 
methods. Serum leptin and adiponectin concentrations were measured using ELISA kits 
according to manufacturer instructions (Invitrogen, Carlsbad, CA) with coefficient of 
variation (CV) for leptin: Intra-assay CV 3.0–3.8% and inter-assay CV 3.9–4.6% (147–884 
pg/mL), and adiponectin intra-assay CV 3.8–3.0% and inter-assay CV 5.2–2.8% (1.9–24.8 
pg/mL). Serum IL-6 and IL-8 were quantified using ELISA kits from BD Biosciences (San 
Jose, CA) according to instructions with the following CV for IL-6: Intra-assay CV 4.1–
10.8% (43.6–146.9 pg/mL) and inter-assay CV 10.9–7.9 % (39.1–147.8 pg/mL) and IL-8: 
Intra-assay CV 4.2–5.5% (27.4–92.1 pg/mL) and 3.4–3.2% (27.2–99.9 pg/mL).
Plasma IGF-1 and IGFBP-1 concentrations were determined using a validated ‘in-house’ 
ELISA assay at the University of Southern California Aging Biomarker Service Core (Los 
Angeles, CA) with CV <10% (24).
Immunohistochemistry
Serial sections for immunohistochemical analyses were cut from archived paraffin 
embedded blocks with the largest cancer volume and with the Gleason grade corresponding 
to the grade on the final pathology report. Slides were stained for Ki67 (monoclonal mouse 
anti-human Ki67 antigen [Dako Omnis/Agilent, Santa Clara, CA]) and TUNEL (ApopTag® 
Plus Peroxidase In Situ Apoptosis Kit [Millipore, Temecula, CA]) (25) to assess 
proliferation and apoptosis, respectively. The areas of adenocarcinoma were circled by the 
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study pathologist (J.S.) Slides were digitized on a ScanScope AT (Aperio Technologies, Inc., 
Vista, CA) and morphimetric analysis performed with Definiens’ Tissue Studio (Definiens 
Inc., Parsippany, NJ) to determine the percentage of Ki67 or TUNEL positive cells in a non-
biased method. Briefly, using the pre-defined nuclear detection module and classification 
tool, positive and negative nuclei within each region of interest were identified. Thresholds 
were set to classify hematoxylin stain for negative nuclei and DAB stain for positive nuclei. 
The data were exported to Excel for further statistical analysis. The number of Ki67 or 
TUNEL-stained nuclei per total cells in the adenocarcinoma region was used to calculate the 
percent of positive stained cells (26). Scanning and analyses were performed through the 
Translational Pathology Core Laboratory, Department of Pathology and Laboratory 
Medicine, David Geffen School of Medicine at UCLA.
Statistical Analysis
A sample size of 65 subjects [no weight loss = 35, weight loss = 30] was estimated to 
provide 80% power to detect an effect size of 0.74 using a two group t-test with a 0.050 two-
sided significance when comparing the apoptotic index (primary outcome variable) in the 
radical prostatectomy malignant epithelium between the WL and no WL groups. To put this 
effect size in context, a similar study looking at a nutritional intervention by Kim et al. 
observed an effect size of 1.81 on apoptotic index using a nutritional intervention with 
similar study characteristics (27). To account for a post-randomization attrition rate of up to 
15% in the WL group, we planned to randomize 35 subjects to the WL group.
After 34 subjects fully completed the trial, an interim analysis was performed to evaluate the 
feasibility of finding a statistically significant difference between the groups for the primary 
outcome. A conditional power analysis demonstrated that, with enrollment of 65 
participants, there was only a 0.9% chance of finding a significant difference in the apoptotic 
index between the treatment and control group. At this point, study enrollment was closed 
and secondary endpoint analyses were performed.
Baseline patient characteristics were compared between groups using mean ± SD and 
frequencies. Secondary outcomes were measured both at baseline and prior to surgery and 
change from baseline to surgery was calculated. Within each group, changes from pre to 
post were calculated using the paired t-test. Next these changes were compared between 
control and WL intervention groups using the two sample t-test. For outcomes that had 
skewed distribution, a log transformation was implored prior to conducting the t-test. P 
values less than 0.05 were considered significant. Statistical analyses were carried out using 
IBM SPSS V24 (Armonk, NY). The data are presented as mean ± SD or SEM where 
appropriate.
RESULTS
Baseline Characteristics
Twenty-three patients were randomized to the WL intervention and twenty-one patients to 
the control group. Seven patients in the WL group and three from the control group 
withdrew from the study with 34 patients completing the trial (Figure 1). The baseline 
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characteristics of the 34 patients that completed the trial are shown in Table 1. All 
participants were overweight or obese. In the WL group, 44% were overweight, 44% obese, 
and 12% morbidly obese at baseline, while, in the control group, 31% were overweight, 44% 
obese, and 25% morbidly obese. Sixty seven percent of patients in the control group and 
69% in the WL group were taking statins. The mean PSA in the WL group was 6.8 ± 2.5 
compared to control group 7.5 ± 8.0 (Table 1). There was no significant difference in age, 
race, ethnicity, statin use, Gleason Score, and disease stage between the two groups (Table 
1).
Body Weight and Composition
The mean time from study enrollment until radical prostatectomy was 62 ± 19 days in the 
control group and 51 ± 16 days in the WL group. Although patients had significant WL in 
both groups, subjects on the WL intervention had more weight loss (−3.7 ± 1.9 kg) 
compared to the control group (−1.6 ± 2.3 kg) (Table 2). Patients in the WL group also had a 
greater decline in BMI (−1.2 ± 0.6) as compared to the control group. (−0.5 ± 0.7) (Table 2). 
The WL intervention group had a greater decrease in fat mass (WL group −2.1 ± 1.8 vs. 
control group 2.2 ± 6.2) and decrease in percent gynoid fat (WL group 1.4 ± 1.9 vs. control 
group 0.2 ± 1.3, Table 2). There was a trend for a greater decrease in percent body fat in the 
WL group (p = 0.06) vs. the control group. No significant change was observed in lean body 
mass, percent trunk fat, and percent android fat between the groups.
Prostate Cancer Tissue Apoptosis and Proliferation
There was no significant difference in apoptotic index in radical prostatectomy tumor tissue 
(Primary Endpoint) as measured by TUNEL between the groups (Figure 2A). Likewise, 
there was no significant difference in the proliferation index as measured by Ki67 staining 
between the groups (Figure 2B).
Serum Lipid, Adipokine, Hormone, Cytokine, and IGF/IGFBP-1
During the intervention period, there was a significant 33% decrease in serum triglyceride 
from 208 ± 194 to 140 ± 79 mg/dL in the WL group, while triglycerides increased in the 
control group from 131 ± 51 to 138 ± 71. Likewise, serum insulin levels decreased in the 
WL group from 17 ± 10 to 13.8 ± 7 and increased in the control group from 12 ± 7 to 14 ± 9 
μIU/mL. There was no significant difference in serum total cholesterol or HDL-cholesterol 
between the WL and control groups (Table 3). There was a significant between group 
difference in LDL-cholesterol levels with a decrease in the control group as compared to the 
WL group. There were no significant between group changes in adipokines, testosterone, 
estradiol, IL-6, IL-8, IGF-1, and IGFBP-1 levels.
DISCUSSION
Obesity is a well-established factor associated with increased risk and mortality of a number 
of human malignancies (28). Given the well-known impact of obesity on prostate cancer 
aggressiveness and mortality and the significant effect of caloric restriction on prostate 
cancer progression in preclinical models, there is strong evidence to support the conduct of 
clinical trials evaluating WL as a therapy for men with prostate cancer. Although the short-
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term WL intervention in our trial did not impact apoptosis or proliferation in radical 
prostatectomy malignant epithelium, biomarker results from our trial and others suggest the 
potential for clinical benefit of WL for men with prostate cancer. For example, a significant 
reduction in percent body fat was observed over the course of the trial. Previous studies 
showed that central body fat mass was associated with increased high-grade prostate cancer 
(14). Likewise, increased periprostatic fat mass was also associated with higher Gleason 
grade (15–17). Iyengar et al. recently reviewed the pro-inflammatory and pro-carcinogenic 
effects of hyperadiposity on the tumor microenvironment, and discussed the link between 
chronic low-grade inflammation and hyperinsulinemia (29). Noteworthy, in the current study 
circulating insulin levels were also reduced in the WL group (−18% compared to +18% in 
the control group), and insulin is a known growth factor for prostate cancer.
A number of short-term clinical studies examined whether WL favorably modifies hormonal 
factors associated with prostate cancer progression. A small (n=11) short-term intensive WL 
intervention with a very low fat diet (<10% kcal from fat) in overweight and obese men was 
found to modify serum factors (IGF-1 decreased by 20%, IGFBP-1 increased by 53%, and 
insulin decreased by 25%) and decreased serum-stimulated growth of LNCaP cells was 
observed in an ex-vivo bioassay (30). It is noteworthy that patients lost more weight in this 
trial (4.2% WL over an 11-day period) as compared to our trial (1.5%WL in the control 
group and 3.7% WL in the treatment group), and in our trial IGF-1 and IGFBP-1 levels did 
not change. Given that the IGF axis may play a key role in the effects of weight loss on 
prostate cancer, it may be that the degree of weight loss in our trial was not adequate to 
affect tissue apoptosis. In another trial, Lin et al. reported that a 6-week low-fat, low-
glycemic load diet resulted in significant WL (5.5%) and gene expression changes in 26 
genes comparing biopsy tissue collected before and after diet intervention (31). In another 
small randomized trial, a 6-week caloric restricted diet in men with prostate cancer resulted 
in significant WL (−1.7%) and an increase in serum IGFBP-3 (+2.8%) compared to controls 
(WL +1%, IGFBP-3 −6.9%) (32). No significant changes in serum insulin, IGF-1 and 
adiponectin were observed (31). Heymach et al. conducted a controlled prospective 
randomized 4-arm pre-prostatectomy trial incorporating a low-fat diet and flax seed. They 
reported that WL significantly correlated with reduction in plasma VEGF levels, TNF-
related apoptosis-inducing ligand (TRAIL) levels, and five other pro-inflammatory cytokines 
(33). Fabian et al demonstrated a 10% weight loss along with a significant decrease in Ki67 
staining in breast cancer tissue (34). Another preprostatectomy weight loss study is ongoing 
(35). These investigators reported 9% weight loss in the intervention group and 6.2% weight 
loss in the control group, but have not yet reported on changes in tumor biomarkers (36).
A number of mechanisms have been proposed linking obesity to advanced prostate cancer. 
As shown in animal studies, alterations in insulin metabolism, IGF-1, IGF binding protein, 
altered serum levels of sex hormones and pro-inflammatory cytokines, and adipokines might 
be involved (37, 38). The IGF axis is a frequently investigated target in prostate cancer since 
it plays an important role in cell proliferation, cell differentiation, apoptosis, and glucose and 
lipid metabolism (39). In a previous study by our group, long-term consumption of a low-
fat/high-fiber diet, including soy for 6 months in prostate cancer patients following radical 
prostatectomy resulted in decreased serum IGF-1 compared with the consumption of the 
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USDA recommended diet (40). In the present trial, we did not find any change in IGF-1 or 
IGFBP-1.
In the current trial, we found a decrease in serum triglycerides, total cholesterol, and fat 
mass, which was expected with WL. A recent meta-analysis found that there was no 
relationship between serum triglyceride and prostate cancer risk (41). Although a decrease in 
fat mass may potentially result in a decrease of inflammatory cells in adipose tissue, we did 
not find any decrease in serum IL-6 or IL-8 levels.
Noteworthy, in our present trial, there was significant WL in the control group (−1.6 ± 2.3 
kg). However, between group comparisons demonstrated significantly more WL in the 
intervention group (−3.7 ± 1.9 kg) as compared to the control group. Through the standard 
consenting process, research subjects are aware of general aspects of the control and 
intervention groups and often desire randomization to the intervention group. Our trial and 
others demonstrated that patients randomized in the control group often self-implement 
behavioral changes and, in this case, achieved WL (42). In our trial, the incremental 
difference in weight loss between the intervention and control group was relatively low at 
2.1 kg. Weight loss in the control group also occurred in other studies (36). Consideration 
should be given to implementing active interventions in the control group to prevent WL. 
Future trials should also consider more intensive weight loss interventions to achieve a 
greater difference in weight loss between the treatment and control groups. In this regard, 
data from our trial may be useful for power calculations for future randomized WL 
intervention trials in men with prostate cancer.
A number of study designs may be appropriate for future WL intervention trials in men with 
prostate cancer. For example, men on active surveillance undergoing targeted same sight 
biopsies may be an ideal study population to undergo a long-term intervention. Another 
population to consider would be men on androgen deprivation for prostate cancer. Androgen 
deprivation is known to increase body fat, making this potentially an ideal population for 
future studies (43). In a prospective randomized trial incorporating diet and exercise, O’Neill 
et al. reported significant WL, reduction in total body fat, and improved functional capacity 
in men on androgen deprivation therapy, though they did not report on biomarkers related to 
prostate cancer progression (44).
There are several limitations to our study. Our trial was a short-term pre-prostatectomy trial, 
and a longer intervention may be required to observe tissue biomarker changes as a result of 
WL. Men in the study lost on average 0.5 kg per week. It appears that participants did not 
completely follow the dietary instructions since they should have lost more weight if eating a 
1200 or 1500 kcal diet. The compliance measure in the present study was weight loss. We 
did not report food intake data and pedometer readings. This information may potentially be 
useful for designing future trials and evaluating compliance. A number of pre-prostatectomy 
dietary intervention trials incorporating dietary supplements such as fish oil and flax seed, 
and increased dietary intake of lycopene rich tomato sauce reported changes in tissue 
biomarkers, but WL without a specific focus on selected dietary nutrients may require longer 
term interventions (27, 45). In addition, our trial was offered to all overweight and obese 
patients undergoing radical prostatectomy at the VA and UCLA. Future research should 
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focus on selecting out specific patients more likely to respond to WL interventions based on 
inflammatory markers and thus incorporate “precision medicine” markers prior to 
enrollment.
CONCLUSION
In summary, our short-term WL program prior to radical prostatectomy resulted in 
significantly more WL in the intervention vs. the control group and was accompanied by 
significant reduction in body fat mass, circulating triglycerides, and insulin levels. However, 
there were no significant changes in malignant epithelium apoptosis or proliferation levels. 
Based on the known association of obesity and lethal prostate cancer, future longer-term or 
more intensive weight loss intervention trials are warranted to further examine if WL has 
therapeutic benefits in men with prostate cancer.
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Figure 1. 
CONSORT Diagram
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Figure 2. 
Effect of WL intervention on proliferation and apoptosis in tumor prostate tissue from post-
intervention radical prostatectomy specimens. A) Ki67 staining and B) TUNEL. Data are 
presented as mean ± SEM for each group (n = 18 control, n = 16 WL). Statistical 
significance was assessed using two independent sample t-test; p ≤ 0.05.
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Figure 3. 
Waterfall plot of weight loss (n = 18 control, n = 16 WL).
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Table 1
Baseline characteristics of study participants
Control (n = 18) Weight Loss (n = 16)
Ethnicity
 Caucasian (No.) 14 11
 Black American (No.) 3 5
 Hispanic (No.) 1 0
Age (y), mean ± SD 61.7 ± 1.5 63.4 ± 1.2
PSA (ng/mL; mean ± SD) 7.5 ± 1.9 6.8 ± 0.6
BMI pre 31.7±1.1 32.9±1.5
Gleason sum at diagnosis (No.)
6 6 4
7 8 9
8–9 4 3
No. of positive cores
Mean ± SD 3.0 ± 2.9 2.8 ± 3.0
Days in Study (d), mean ± SD 61.7 ± 4.2 51.3 ± 3.9
Days in Study (d), range 33–96 29–89
Values presented as Mean ± SEM or frequency.
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Table 2
Changes in body composition
Study Outcomes Control WL p-value
Post-intervention minus pre-intervention Post-intervention minus pre-intervention
Weight (kg) −1.6 ± 0.5
−3.7 ± 0.5** 0.007
BMI (kg/m2) −0.5 ± 0.2
−1.2 ± 0.6** 0.005
Waist (cm) −0.4 ± 0.2 1.0 ± 0.3 0.113
Hip (cm) −1.2 ± 0.7 −0.5 ± 0.45 0.390
Fat mass (kg) 0.1 ± 0.3
−2.1 ± 0.4* 0.015
Lean mass (kg) −0.7 ± 0.4 −1.6 ± 0.6 0.304
Body fat (%) 0.4 ± 0.3 −0.9 ± 0.5 0.063
Trunk fat (%) 0.6 ± 0.4 −0.9 ± 0.7 0.125
Gynoid fat (%) 0.2 ± 0.4
−1.4 ± 0.5* 0.032
Android fat (%) 0.6 ± 0.3 −1.0 ± 0.8 0.156
Data represent mean ± SEM. N = 18 for control and n = 16 for WL group. Within each group the difference between baseline and end of 
intervention was evaluated using paired t-test;
*p ≤ 0.05,
**p<0.01.
Changes between groups were calculated using two independent sample t-test.
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Table 3
Changes in metabolic and inflammatory biomarkers
Study Outcomes Control WL p-valuea
Post-intervention minus pre-intervention Post-intervention minus pre-intervention
Triglyceride (mg/dL) 7.0 ± 9.3
−67.5 ± 30.1* 0.019
Cholesterol (mg/dL) −9.7 ± 5.9 −6.1 ± 6.1 0.672
LDL-Chol (mg/dL) −11.2 ± 5.7 5.4 ± 5.2* 0.041
HDL-Chol (mg/dL) 0.06 ± 1.4 −0.8 ± 1.0 0.639
Leptin (pg/mL) 22.6 ± 77.5 −141.2 ± 99.7 0.201
Adiponectin (pg/mL) 0.3 ± 0.6 0.06 ± 0.6 0.783
Leptin/Adiponectin Ratio 3.3±18 −23.6±62 0.147
Insulin (μlU/mL) 2.1 ± 1.6
−3.2 ± 1.9* 0.035
Total Testosterone (ng/dL) −22.4 ± 24.8 27.1 ± 19.8 0.135
Free Testosterone (ng/dL) −4.6 ± 2.8 0.8 ± 1.1 0.083
Estradiol −4.9 ± 2.2 −0.5 ± 3.7 0.307
IL-6 (pg/mL) 4.1 ± 3.0 0.1 ± 1.4 0.234
IL-8 (pg/mL) −28.1 ± 16.3 33.7 ± 32.3 0.092
IGF-1 (ng/mL) −3.1 ± 3.9 7.4 ± 1.8 0.186
IGFBP-1 (ng/mL) −0.03 ± 7.4 2.2 ± 1.5 0.353
Data represent mean ± SEM. N = 18 for control and n = 16 for WL group. Within each group the difference between baseline and end of 
intervention was evaluated using Student’s t-test.
*p ≤ 0.05.
Changes between groups were calculated using two independent sample t-test.
alists p-values.
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